Novo Nordisk raises outlook fuelled by obesity drug demand

​​​​​​Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected quarterly profits as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from rival Eli Lilly.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/T28MDeZ
via